Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Nov 18, 2024Closes
Jan 7, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Education, Health
Eligible applicants: County governments, Special district governments, Native American tribal organizations (other than Federally recognized tribal governments), Small businesses, Independent school districts, For profit organizations other than small businesses, City or township governments, Private institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, State governments, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Native American tribal governments (Federally recognized)
Description
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.